UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Candidate biomarkers of PARP inhibitor sensitivity in ovarian cancer beyond the BRCA genes

British journal of cancer, 2018-11, Vol.119 (11), p.1401-1409

2018

Volltextzugriff (PDF)

Long-Term Responders on Olaparib Maintenance in High-Grade Serous Ovarian Cancer: Clinical and Molecular Characterization

Clinical cancer research, 2017-08, Vol.23 (15), p.4086-4094

2017

Volltextzugriff (PDF)

Defining actionable mutations for oncology therapeutic development

Nature reviews. Cancer, 2016-05, Vol.16 (5), p.319-329

2016

Volltextzugriff (PDF)

Biological and clinical evidence for somatic mutations in BRCA1 and BRCA2 as predictive markers for olaparib response in high-grade serous ovarian cancers in the maintenance setting

Oncotarget, 2017-07, Vol.8 (27), p.43653-43661

2017

Volltextzugriff (PDF)

Concordance of BRCA mutation detection in tumor versus blood, and frequency of bi-allelic loss of BRCA in tumors from patients in the phase III SOLO2 trial

Gynecologic oncology, 2021-12, Vol.163 (3), p.563-568

2021

Volltextzugriff (PDF)

Clinically Viable Gene Expression Assays with Potential for Predicting Benefit from MEK Inhibitors

Clinical cancer research, 2017-03, Vol.23 (6), p.1471-1480

2017

Volltextzugriff (PDF)

Biomarkers in oncology drug development

Molecular oncology, 2009-02, Vol.3 (1), p.24-32

2009

Volltextzugriff (PDF)

Correlation between MEK signature and Ras gene alteration in advanced gastric cancer

Oncotarget, 2017-12, Vol.8 (64), p.107492-107499

2017

Volltextzugriff (PDF)

Practical perspectives of personalized healthcare in oncology

New biotechnology, 2012-09, Vol.29 (6), p.656-664

2012

Volltextzugriff (PDF)

Circulating tumour-derived predictive biomarkers in oncology

Drug discovery today, 2010-02, Vol.15 (3), p.98-101

2010

Volltextzugriff (PDF)

Development of a facile fluorescent assay for the detection of 80 mutations within the p53 gene

Molecular medicine (Cambridge, Mass.), 2002-05, Vol.8 (5), p.227-237

2002

Volltextzugriff (PDF)

Olaparib combined with abiraterone in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): A randomized phase II trial

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.5003-5003

2018

Volltextzugriff (PDF)

Analysis of tumor samples from SOLO2: Concordance of BRCA mutation ( BRCA m) detection in tumor vs. blood and frequency of BRCA -specific loss of heterozygosity (LOH) and loss of function somatic mutations

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.12017-12017

2018

Volltextzugriff (PDF)

Locus-specific loss of heterozygosity (LOH) in BRCA1/2 mutated (mBRCA) ovarian tumors from the SOLO2 (NCT01874353) and Study 19 (NCT00753545) clinical trials

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.5563-5563

2018

Volltextzugriff (PDF)

Tumor molecular profiling to differentiate extreme responses to first-line platinum-based chemotherapy in suboptimally debulked serous ovarian cancer patients

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.5561-5561

2018

Volltextzugriff (PDF)

Candidate predictive biomarkers for response to olaparib in advanced gastric cancer (AGC)

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.4041-4041

2016

Volltextzugriff (PDF)

Abstract 611: Exploratory analyses suggest ovarian tumors with somatic or germline loss of function mutations in BRCA1 or BRCA2 are biologically similar and sensitive to PARP inhibition

Cancer research (Chicago, Ill.), 2015-08, Vol.75 (15_Supplement), p.611-611

2015

Volltextzugriff (PDF)

Analysis of candidate homologous repair deficiency genes in a clinical trial of olaparib in patients (pts) with platinum-sensitive, relapsed serous ovarian cancer (PSR SOC)

Journal of clinical oncology, 2014-05, Vol.32 (15_suppl), p.5536-5536

2014

Volltextzugriff (PDF)

Genomic characterization of long-term responders to olaparib

Journal of clinical oncology, 2015-05, Vol.33 (15_suppl), p.5566-5566

2015

Volltextzugriff (PDF)

Assessment of the variability of and effect of hormone therapy on circulating tumor cell numbers and androgen receptor expression in patients with prostate cancer

Journal of clinical oncology, 2012-05, Vol.30 (15_suppl), p.e15141-e15141

2012

Volltextzugriff (PDF)

Free-ligand accelerated dissociation of insulin-like growth factor 1 (IGF-1) from the type I IGF receptor is reduced by insulin-like growth factor binding protein 3

Regulatory peptides, 2000-06, Vol.90 (1), p.33-37

Hodgson, Darren R.

2000

Volltextzugriff (PDF)

ARMS allele-specific amplification-based detection of mutant p53 DNA and mRNA in tumors of the breast

Clinical chemistry (Baltimore, Md.), 2001-04, Vol.47 (4), p.774-778

2001

Volltextzugriff (PDF)

Involvement of phenylalanine 23 in the binding of IGF-1 to the insulin and type I IGF receptor

Regulatory peptides, 1996-10, Vol.66 (3), p.191-196

1996

Volltextzugriff (PDF)

ARMSallele-specific amplification-based detection of mutant p53 DNA and mRNA in tumors of the breast

Clinical chemistry (Baltimore, Md.), 2001, Vol.47 (4), p.774-778

2001

Volltextzugriff (PDF)

1 – 25 von 50

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(47)
Mit Volltextzugriff
(47)

Publikationsform

Artikel
(50)

Sprache

Englisch
(50)

Erscheinungsjahr

n.n

Thema

Science & Technology
(27)
Humans
(23)
Life Sciences & Biomedicine
(23)
Oncology
(14)
Mutation
(11)
Female
(10)
Biological And Medical Sciences
(9)
Animals
(6)
Biomarkers
(6)
Tumors
(6)
Cancer
(5)
Fundamental And Applied Biological Sciences. Psychology
(5)
Male
(5)
Medical Sciences
(5)
Ovarian Cancer
(5)
Ovarian Neoplasms - Genetics
(5)
Patients
(5)
Biomarkers, Tumor - Blood
(4)
Brca2 Protein - Genetics
(4)
Breast Cancer
(4)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Candidate biomarkers of PARP inhibitor sensitivity in ovarian cancer beyond the BRCA genes

Long-Term Responders on Olaparib Maintenance in High-Grade Serous Ovarian Cancer: Clinical and Molecular Characterization

Defining actionable mutations for oncology therapeutic development

Biological and clinical evidence for somatic mutations in BRCA1 and BRCA2 as predictive markers for olaparib response in high-grade serous ovarian cancers in the maintenance setting

Concordance of BRCA mutation detection in tumor versus blood, and frequency of bi-allelic loss of BRCA in tumors from patients in the phase III SOLO2 trial

Identifying homologous recombination deficiency in breast cancer: genomic instability score distributions differ among breast cancer subtypes

Clinically Viable Gene Expression Assays with Potential for Predicting Benefit from MEK Inhibitors

Biomarkers in oncology drug development

Correlation between MEK signature and Ras gene alteration in advanced gastric cancer

Practical perspectives of personalized healthcare in oncology

Circulating tumour-derived predictive biomarkers in oncology

Development of a facile fluorescent assay for the detection of 80 mutations within the p53 gene

Olaparib combined with abiraterone in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): A randomized phase II trial

Analysis of tumor samples from SOLO2: Concordance of BRCA mutation ( BRCA m) detection in tumor vs. blood and frequency of BRCA -specific loss of heterozygosity (LOH) and loss of function somatic mutations

Locus-specific loss of heterozygosity (LOH) in BRCA1/2 mutated (mBRCA) ovarian tumors from the SOLO2 (NCT01874353) and Study 19 (NCT00753545) clinical trials

Tumor molecular profiling to differentiate extreme responses to first-line platinum-based chemotherapy in suboptimally debulked serous ovarian cancer patients

Candidate predictive biomarkers for response to olaparib in advanced gastric cancer (AGC)

Abstract 611: Exploratory analyses suggest ovarian tumors with somatic or germline loss of function mutations in BRCA1 or BRCA2 are biologically similar and sensitive to PARP inhibition

Analysis of candidate homologous repair deficiency genes in a clinical trial of olaparib in patients (pts) with platinum-sensitive, relapsed serous ovarian cancer (PSR SOC)

Genomic characterization of long-term responders to olaparib

Assessment of the variability of and effect of hormone therapy on circulating tumor cell numbers and androgen receptor expression in patients with prostate cancer

Free-ligand accelerated dissociation of insulin-like growth factor 1 (IGF-1) from the type I IGF receptor is reduced by insulin-like growth factor binding protein 3

ARMS allele-specific amplification-based detection of mutant p53 DNA and mRNA in tumors of the breast

Involvement of phenylalanine 23 in the binding of IGF-1 to the insulin and type I IGF receptor

ARMSallele-specific amplification-based detection of mutant p53 DNA and mRNA in tumors of the breast

Suchergebnisse filtern